2018 American Transplant Congress
Pharmacokinetics of Mycophenolic Acid Following Enteric-Coated Mycophenolate Sodium Administration in Chinese Renal Transplant Recipients
MyERA Study Group, Hangzhou, China.
Background: Mycophenolic acid (MPA), active component of mycophenolate mofetil (MMF) or enteric-coated mycophenolate sodium (EC-MPS), is the most commonly used immunosuppressant in renal transplant recipients…2018 American Transplant Congress
A Six-Month, Prospective, Single-Center, Pilot Study to Determine the Pharmacokinetics and Effectiveness of Immunosuppressant Regimens in Liver Transplantation Patients Receiving Twice-Daily Tacrolimus and Everolimus (TAC + EVR BID) Regimen Converted to Once-Daily Tacrolimus and Everolimus (TAC + EVR QD) Regimen – A Priliminary Report
Adherence to immunosuppressant regimen is crucial for graft survival and usually inversely related to the dose frequency. Similar efficacy and safety profile has been approved…2018 American Transplant Congress
Evaluation of Clinical and Safety Outcomes Following Uncontrolled Tacrolimus Conversion in Adult Transplant Recipients
Background: Long-term studies with control groups are required to assess tacrolimus (TAC) conversion. The purpose of this study was to compare clinical and safety outcomes…2018 American Transplant Congress
Tacrolimus Metabolism in Subjects with Potentially Absent CYP3A Activity
Purpose: Tacrolimus (TAC) is a well-known cytochrome P450 (CYP) 3A4 and 3A5 substrate. Common single nucleotide polymorphisms (SNPs) in these genes are significantly related to…2018 American Transplant Congress
Tacrolimus Pharmacokinetics (PK) at Low, Medium, and High Trough Levels in Patients Converted from Twice-Daily Immediate-Release Tacrolimus (TacBID) to Once-Daily Extended-Release Tacrolimus (LCPT)
LCPT (Envarsus XR®) is a once-daily, extended-release formulation of tacrolimus which has demonstrated greater bioavailability and a smoother PK profile compared to TacBID. This post-hoc…2018 American Transplant Congress
Association of CYP3A5*3*6*7 Metabolic Composites to Tacrolimus Pharmacokinetics in African American and Caucasian Renal Transplant Recipients
Background: Interpatient variability in tacrolimus pharmacokinetics(PK) is due primarily to metabolism by cytochrome P-450 3A5(CYP3A5) isoenzymes. African Americans(AA) require higher tacrolimus doses to achieve comparable…2018 American Transplant Congress
The Providers Can't Let Go! An Analysis of an RN Driven Tacrolimus Dose Adjustment Protocol
Introduction: Tacrolimus (FK) dose adjustment is frequently performed by non-MD staff. Standard protocols to evaluate the ability of non-providers to maintain pts within a goal…2018 American Transplant Congress
Institution-Based, Pharmacist-Managed Anticoagulation in Patients with a Left Ventricular Assist Device
Long-term anticoagulation with warfarin is required for patients with left ventricular assist devices (LVADs). There is limited data of time in therapeutic range (TTR) in…2018 American Transplant Congress
Single-Dose Pharmacokinetics and Pharmacodynamics of Belatacept in Adolescent Kidney Transplant Recipients
Purpose: To assess the pharmacokinetics (PK) and pharmacodynamic (PD) effect of a single dose of belatacept (bela) administered to adolescent kidney transplant recipients (KTR).Methods: In…2017 American Transplant Congress
The Polymer Pro-Drug APP-103 Mitigates I/R Injury and Improves Graft Function in a Pre-Clinical Renal Transplant Model.
Purpose: Ischemia-reperfusion injury (IRI) is the strongest non-HLA factor that augments allogenicity of transplanted organs. Damage subsequent to IRI is critically linked to an abundance…
- « Previous Page
- 1
- …
- 5
- 6
- 7
- 8
- 9
- …
- 12
- Next Page »